Detalhe da pesquisa
1.
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2.
Proc Natl Acad Sci U S A
; 121(6): e2317756121, 2024 Feb 06.
Artigo
Inglês
| MEDLINE | ID: mdl-38300868
2.
Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers.
Cell Rep
; 38(5): 110291, 2022 02 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35108525